Hepatocellular carcinoma: guideline history
No version history recorded yet for this cancer; the concordance rows below compare what each body says today.
Where the bodies stand today
1 of 1 settings
| Setting and intervention | NCCN | ESMO | NICE | ASCO | Verdict |
|---|---|---|---|---|---|
Hepatocellular carcinoma · Unresectable, first line Atezolizumab plus bevacizumab (IMbrave150) | Preferred Category 1, preferred 2020-06 | Recommended I, A; ESMO-MCBS 4 2021 | Recommended TA666 2020-12 | · | Bodies agree |
Other cancers
Acute myeloid leukaemiaBladder & urothelial cancerCervical cancerChronic lymphocytic leukaemiaColorectal cancerDiffuse large B-cell lymphomaEndometrial cancerGastric & gastro-oesophageal junction cancerHER2-positive breast cancerHR-positive / HER2-negative breast cancerMelanomaMultiple myelomaNon-small-cell lung cancerOesophageal cancerOvarian cancerProstate cancerRenal cell carcinomaTriple-negative breast cancer (TNBC)
Each entry is anchored to a dated public event and links to the guideline body’s page for the disease; NCCN “Summary of changes” pages sit behind a free login and are not reproduced. Version labels say “update” where the NCCN version number has not been verified. Corrections are welcome via the repository.